Smilow Cancer Hospital at Yale-New Haven Celebrates Anniversary
It's hard to believe that the first patient was seen in the radiation oncology unit of Smilow Cancer Hospital a little over a year ago.
The hard work and dedication of all the physicians, nurses, and staff over the last year has ensured the successful transition of our patients to the new building.
Since opening, 22,500 patient visits have occurred in Smilow and we have added 336 new full-time staff members to support the oncology services.
The occupancy rate on the inpatient oncology floor is at 84%, outpatient visits with chemotherapy have increased by 5%, and the gamma knife utilization is up 47%.
We will continue to transition the remaining cancer services to Smilow Cancer Hospital over the next several months.
The endocrine surgery team will move in December, the head and neck surgeons will move in January, and lastly the genitourinary cancer surgeons will transition in March.
In addition, the endoscopy team will move to the 8th floor in January.
Yale Cancer Center and Smilow Cancer Hospital will continue to partner together to strengthen the cancer services available to our patients as we strive to make Smilow Cancer Hospital a top tier cancer hospital in the country.
Thank you for your continued support to help us reach this goal.
External Scientific Advisory Board (ESAB) Meeting
Yale Cancer Center will host 14 members of our scientific advisory board on Thursday, November 18th and Friday, November 19th at Smilow Cancer Hospital. In addition to an update from the Yale Cancer Center, Yale-New Haven Hospital, and Yale School of Medicine leadership, board members will hear presentations on each of the cancer center research programs. A review of clinical trial operations and an overview of shared resources available to Yale Cancer Center membership will also be presented.
Yale-New Haven Hospital Listed by Becker's Hospital Review for Oncology Programs
Becker's Hospital Review
included Yale-New Haven Hospital on their list of the top 30 hospitals in the country with great oncology programs.
The list was developed based on an analysis of data from U.S. News & World Report, HealthGrades, American Nurses Credentialing Center, and the Cancer Information Network.
Yale Hosts International Thymic Malignancies Interest Group (ITMIG)
On November 16-17, Yale will host dozens of researchers and clinicians who are interested in working together to create practice standards, a thymic malignancy staging system, and a prospective ITMIG database.
Dr. Frank Detterbeck is President of the group, which includes approximately 250 members from around the globe.
Several faculty members from Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will be in attendance and presenting their research at the upcoming Annual Society of Hematology meeting. Congratulations to the following faculty members for their participation:
Member of the Scientific Program Committee
Moderator for the Scientific Session: Hematopoiesis - Microenvironment, Cell Adhesion and Mesenchymal Stem Cells
Coordinator of the Pre-ASH Workshop: Myeloid Cell Biology and Leukemia
Moderator for the Scientific Session: Oncogenes and Tumor Suppressors: Genomic Approaches and Disease Gene Discovery
Francine Foss Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF) Madhav Dhodapkar Predicting Disease Progression to Myeloma from MGUS in SWOG0120 Observational Trial Stephanie Massaro, Elenoe Smith, and Diane Krause
Modeling Megakaryopoiesis and Leukemogenesis Using Human and Murine Embryonic Stem Cells
Iris Isufi, Amy Barile, Kerry Russell, Kasia Hryniewicz, Julie Baker, Erin Medoff, Daniel Jacoby, Forrester Lee, Francine Foss, Dennis Cooper, and Stuart Seropian
Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction
Susannah Helene Kassmer, Emanuela Bruscia, Ping-Xia Zhang, and Diane Krause
Bone Marrow Derived Lung Epithelial Cells Are Derived Predominantly From Nonhematopoietic Cells
Dr. Herbert Yu
was recently awarded a $6.98 million grant from the National Cancer Institute to fund a five-year
epidemiologic study of hepatocellular carcinoma in the United States.
The research team will study the environmental and genetic factors that may play a role in the increasing incidence of liver cancer.
Dr. Michelle Sowden
, the 4th Norma Lies Mitchell Breast Fellow funded by the Breast Cancer Alliance, recently received first prize from the Connecticut Chapter of the American College of Surgeons for her presentation at the annual Connecticut American Cancer Society Chapter meeting. Her presentation was on the Accuracy of Intraoperative Assessment of Sentinel Lymph Nodes in Breast Cancer over 7 Years and Dr. Brigid Killelea mentored her for the project.
Dr. Nita J. Maihle
presented a plenary lecture at this week's 9th Annual AACR International Conference in Cancer Prevention Research. The title of her presentation was
The EGFR Conundrum: EGFR-based Diagnostics in the Era of Personalized Medicine
Dr. Jason Wilken will be presenting an invited lecture on the topic sEGFR Is an Alternate Target of EGFR-directed Therapeutic Antibodies during the 2010 Ovarian Cancer Research Symposium, to be held in Seattle, WA. He also has been invited to present an informal lecture to patient advocates as part of this year's symposium.
Drs. Anees Chagpar
and Mark Faries presented at the Western Surgical Association Annual Meeting last weekend.
Dr. Chagpar presented
Lymph Node Ratio Improves Axillary Staging in Breast Cancer Patients
and Dr. Faries spoke on the topic, Are the Popliteal and Inguinal Basins Functionally Separate in Melanoma?
Research in the News
Exercise is Associated with Reduced Risk of Endometrial Cancer
Women who routinely perform moderate- to vigorous-intensity exercise for 2.5 hours or more weekly have a significantly reduced risk of endometrial cancer, new research by the Yale School of Public Health has discovered.
The study examined hundreds of women and found that those who exercised at least 150 minutes weekly-which could be something as simple as moderate-paced walking-had a 34 percent reduced risk of endometrial cancer compared with their sedentary peers.
Colorectal Cancer Coalition-AACR Fellowship, in memory of Lisa Dubow
The Colorectal Cancer Coalition-AACR Fellowship, in memory of Lisa Dubow, is a one-year grant of $45,000 to support the salary and benefits of the fellow. A partial amount of funds, up to 25 percent of the total grant, may be designated for direct research expenses. Research projects are restricted to translational or clinical cancer research that has an ultimate goal of developing or improving therapeutic interventions for patients with metastatic colorectal cancer.
Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research
Open to junior faculty who have completed postdoctoral or clinical research fellowships on or after July 2, 2007 and hold a full-time faculty appointment. Proposed research projects may be in any discipline of cancer prevention research and must describe novel and innovative research that, if successful, will have strong potential for high impact in the cancer prevention field.
Landon Foundation-AACR INNOVATOR Award for Research in Personalized Cancer Medicine
Open to independent investigators, this grant is designed to accelerate progress in the area of personalized cancer medicine by providing support for a researcher conducting meritorious studies that hold promise for near-patient benefit. Research projects may be in any discipline of clinical or translational cancer research, provided they will have an impact on the field of personalized cancer medicine.
Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research
Open to two or more independent investigators working within an established international cancer research collaboration involving institutes in multiple countries. Collaborative research projects can be in any discipline of basic, clinical, translational, or epidemiological cancer research. Applications must demonstrate the collaboration's utilization of unique populations and environments, shared resources, specialized expertise, new concepts and perspectives, innovative methodologies, and/or emerging technologies within a cancer research project.
AACR Calls for SU2C Innovative Research Grant Letters of Intent
The American Association for Cancer Research calls upon the cancer research community to submit Letters of Intent for Stand Up To Cancer's Innovative Research Grants (IRG), which support the next generation of extraordinary cancer research leaders in their quest to conquer cancer.
The grants will provide funding of up to $750,000 over a three-year period.
IRGs offer financial support to scientists pursuing novel, high-risk, but potentially high-reward cancer research proposals that have significant potential for translational application and hold great promise for advancing SU2C's overarching goal of improving and saving lives. Proposals may focus on any discipline within basic, translational or clinical research, provided that these criteria are met.
Sidney Kimmel Foundation Translational Science Award
The foundation provides these awards specifically for physicians engaged in translational science. Applicants must demonstrate a significant personal involvement in the laboratory component of the translational project described. The translational research may involve primarily animal studies but must include reasonable application to subsequent human investigation.
Sidney Kimmel Foundation for Cancer Research Scholars Award
Each year the Kimmel Foundation expects to select up to ten grant recipients for the Scholars Award who will receive $100,000 per year for two years. Qualified applicants must hold an MD, PhD, or equivalent graduate degree and must perform research in an American not-for-profit institution during the period of Kimmel Foundation support.
The Kimmel Foundation is seeking accomplished young investigators dedicated to a career in cancer research. Applications are limited to those who achieved the equivalent rank of Assistant Professor on or after July, 2007.
National Disease Research Interchange (NDRI) Cancer Tissue Program
To meet the growing demands of cancer researchers, NDRI is expanding its efforts to increase the availability of cancer samples from surgical donors. This new initiative permits rapid sample procurement (within ~1 hour) and shipment, so researchers can receive their samples within 24 hours of the surgery. Detailed donor information, including a pathology report with tumor diagnosis, is provided with each sample. Listed below are representative samples from this program.
Surgical Cancer Samples
· Breast · Lung
· Endometrial · Colon
· Ovarian · Kidney
In addition to the surgical samples, also we encourage cancer researchers to view the diverse assortment of cancer and normal control tissue samples in the NDRI Online Biospecimen Catalog.
Ethical issues surrounding fertility preservation in cancer patients.
Patrizio P, Caplan AL.
Clin Obstet Gynecol. 2010 Dec;53(4):717-26.
Read More >>
Should the 7th edition of the lung cancer stage classification system change treatment algorithms in non-small cell lung cancer?
Boffa DJ, Detterbeck FC, Smith EJ, Rami-Porta R, Crowley J, Zelterman D, Tanoue L, Kim AW, Goldstraw P.
J Thorac Oncol. 2010 Nov;5(11):1779-83.
Read More >>
Transient brachial plexus palsy: an unusual complication of paravertebral infusion of local anesthetic.
D'Souza D, Sondergaard K, Detterbeck FC.
Ann Thorac Surg. 2010 Nov;90(5):e75-6.
Read More >>
International thymic malignancies interest group: a way forward.
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S365-70.
Read More >>
Medullary thyroid cancer: an update of new guidelines and recent developments.
Wu LS, Roman SA, Sosa JA.
Curr Opin Oncol. 2010 Oct 30.
Read More >>
Tracing the origins of metastasis.
J Pathol. 2010 Oct 6.
Read More >>
Small intestinal neuroendocrine cell pathobiology: 'carcinoid' tumors.
Kidd M, Modlin IM.
Curr Opin Oncol. 2010 Oct 30.
Read More >>
Expression and somatic mutations of SDHAF2 (SDH5), a novel endocrine tumor suppressor gene in parathyroid tumors of primary hyperparathyroidism.
Starker LF, Delgado-Verdugo A, Udelsman R, Björklund P, Carling T.
Endocrine. 2010 Oct 23.
Read More >>